Matrix metalloproteinases and aggrecanases cleave aggrecan in different zones of normal cartilage but colocalize in the development of osteoarthritic lesions in STR/ort mice.
OBJECTIVE
To map aggrecan cleavage by matrix metalloproteinases (MMPs) and aggrecanases in normal murine tibial articular cartilage (CBA strain) and in the development of spontaneous osteoarthritis (OA) in the STR/ort mouse and to assess the influence of sex hormone status on these conditions in gonadectomized STR/ort mice.


METHODS
The distributions of neoepitopes of aggrecan generated by MMP (VDIPEN) and aggrecanase (NITEGE) cleavage were investigated by immunohistochemistry.


RESULTS
VDIPEN neoepitope was detected mainly in the pericellular matrix of deep-zone chondrocytes in normal tibial cartilage from STR/ort and CBA mice. In early OA, VDIPEN immunostaining also localized to the pericellular matrix of chondrocytes at the site of the lesion. With increasing severity of OA lesions, VDIPEN immunostaining was also detected in the interterritorial matrix, close to the site of the lesion. In contrast, NITEGE mapped most strongly to the pericellular matrix of upper-zone chondrocytes in normal tibial cartilage. As with VDIPEN, NITEGE was strongly expressed in the pericellular matrix at the site of early OA lesions. With advancing OA, NITEGE colocalized with VDIPEN in both the pericellular and interterritorial matrices of chondrocytes adjacent to OA lesions and in those of the deep zones. Hormone status did not appear to influence the development of OA or the distribution of aggrecan neoepitopes in STR/ort mice.


CONCLUSIONS
MMP- and aggrecanase-generated neoepitopes map predominantly to different regions in normal murine tibial cartilage. However, both groups of enzymes generate increased amounts of neoepitopes in pericellular and interterritorial matrix adjacent to histopathologic lesions of OA. Aggrecan degradation and the development of OA appear to be independent of sex hormone status in this model.
Chambers
M G
MG
Imperial College School of Medicine, London, UK.
Cox
L
L
Chong
L
L
Suri
N
N
Cover
P
P
Bayliss
M T
MT
Mason
R M
RM
D053674:Aggrecans; D000818:Animals; D002358:Cartilage, Articular / Q000166:cytology / Q000201:enzymology* / Q000473:pathology; D019902:Chondrocytes / Q000737:chemistry / Q000166:cytology / Q000473:pathology; D010450:Endopeptidases / Q000378:metabolism*; D000939:Epitopes / Q000032:analysis; D005109:Extracellular Matrix / Q000737:chemistry; D016326:Extracellular Matrix Proteins; D019084:Fluorescent Antibody Technique, Indirect; D037181:Lectins, C-Type; D008297:Male; D020782:Matrix Metalloproteinases / Q000378:metabolism*; D051379:Mice; D008808:Mice, Inbred CBA; D009842:Oligopeptides / Q000032:analysis; D020370:Osteoarthritis, Knee / Q000201:enzymology* / Q000473:pathology; D010052:Ovariectomy; D010446:Peptide Fragments / Q000032:analysis; D011509:Proteoglycans / Q000378:metabolism*; D013264:Stifle / Q000737:chemistry / Q000201:enzymology / Q000473:pathology
C508320:Acan protein, mouse; D053674:Aggrecans; D000939:Epitopes; D016326:Extracellular Matrix Proteins; D037181:Lectins, C-Type; D009842:Oligopeptides; D010446:Peptide Fragments; D011509:Proteoglycans; C093378:peptide VDIPEN; D010450:Endopeptidases; D020782:Matrix Metalloproteinases; C083641:aggrecanase